ASX:MSBBiotechs
The Bull Case For Mesoblast (ASX:MSB) Could Change Following Surging Ryoncil Revenue And 2026 Guidance - Learn Why
In late February 2026, Mesoblast reported half-year results showing revenue of US$51.34 million, a very large increase from US$3.16 million a year earlier, alongside a narrower net loss of US$40.16 million and reduced loss per share.
Soon after, the company issued fiscal 2026 guidance projecting full-year Ryoncil net revenue between US$110 million and US$120 million, giving investors a clearer view of the therapy’s commercial trajectory.
With Mesoblast now guiding Ryoncil net revenue of...